AU2014307437B2 - Novel fused pyrimidine compound or salt thereof - Google Patents
Novel fused pyrimidine compound or salt thereof Download PDFInfo
- Publication number
- AU2014307437B2 AU2014307437B2 AU2014307437A AU2014307437A AU2014307437B2 AU 2014307437 B2 AU2014307437 B2 AU 2014307437B2 AU 2014307437 A AU2014307437 A AU 2014307437A AU 2014307437 A AU2014307437 A AU 2014307437A AU 2014307437 B2 AU2014307437 B2 AU 2014307437B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- amino
- oxazol
- pyrimidine
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013-167600 | 2013-08-12 | ||
| JP2013167600 | 2013-08-12 | ||
| PCT/JP2014/071158 WO2015022926A1 (ja) | 2013-08-12 | 2014-08-11 | 新規な縮合ピリミジン化合物又はその塩 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014307437A1 AU2014307437A1 (en) | 2016-01-21 |
| AU2014307437B2 true AU2014307437B2 (en) | 2016-12-15 |
Family
ID=52468312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014307437A Active AU2014307437B2 (en) | 2013-08-12 | 2014-08-11 | Novel fused pyrimidine compound or salt thereof |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9580432B2 (enExample) |
| EP (1) | EP2947086B1 (enExample) |
| JP (1) | JP6035423B2 (enExample) |
| KR (1) | KR101828187B1 (enExample) |
| CN (1) | CN105452257B (enExample) |
| AU (1) | AU2014307437B2 (enExample) |
| BR (1) | BR112016002069B1 (enExample) |
| CA (1) | CA2921208C (enExample) |
| DK (1) | DK2947086T3 (enExample) |
| ES (1) | ES2661733T3 (enExample) |
| HU (1) | HUE036834T2 (enExample) |
| MX (1) | MX360498B (enExample) |
| MY (1) | MY171831A (enExample) |
| NO (1) | NO2947086T3 (enExample) |
| PH (1) | PH12015502737B1 (enExample) |
| PL (1) | PL2947086T3 (enExample) |
| PT (1) | PT2947086T (enExample) |
| RU (1) | RU2666349C2 (enExample) |
| SG (1) | SG11201600048VA (enExample) |
| TR (1) | TR201802875T4 (enExample) |
| TW (1) | TWI585089B (enExample) |
| WO (1) | WO2015022926A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170050936A1 (en) | 2013-08-23 | 2017-02-23 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| SG11201704431VA (en) | 2015-01-30 | 2017-09-28 | Taiho Pharmaceutical Co Ltd | Novel salt of fused pyrimidine compound and crystal thereof |
| CN107206001B (zh) * | 2015-01-30 | 2021-09-28 | 大鹏药品工业株式会社 | 免疫疾病的预防剂和/或治疗剂 |
| PT3345907T (pt) * | 2015-09-01 | 2020-06-23 | Taiho Pharmaceutical Co Ltd | Compostos de pirazolo[3,4-d]pirimidina ou sais dos mesmos |
| MA41559A (fr) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
| TWI642671B (zh) * | 2015-10-28 | 2018-12-01 | 台灣神隆股份有限公司 | 依魯替尼之製備方法及其中間體 |
| EP3269370B1 (en) | 2016-02-23 | 2020-01-08 | Taiho Pharmaceutical Co., Ltd. | Novel condensed pyrimidine compound or salt thereof |
| EP4006035B1 (en) * | 2016-08-15 | 2023-11-22 | Neupharma, Inc. | Quinazoline derivatives as tyrosine kinase inhibitors for the treatment of cancer |
| JP7223684B2 (ja) * | 2017-02-28 | 2023-02-16 | 大鵬薬品工業株式会社 | ピラゾロ［３，４－ｄ］ピリミジン化合物を用いた抗腫瘍効果増強剤 |
| EP3674325A4 (en) | 2017-08-21 | 2021-11-03 | Taiho Pharmaceutical Co., Ltd. | FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN |
| PL3909584T3 (pl) * | 2019-01-11 | 2024-03-25 | Taiho Pharmaceutical Co., Ltd. | Związek pirymidynowy lub jego sól |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| US20230064254A1 (en) | 2019-12-19 | 2023-03-02 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent containing fused pyrimidine compound as active ingredient |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230255972A1 (en) * | 2020-07-15 | 2023-08-17 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN114736207B (zh) * | 2022-04-28 | 2023-03-31 | 武汉九州钰民医药科技有限公司 | 一种小分子her2抑制剂的制备工艺 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013108809A1 (ja) * | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | ３，５－二置換ベンゼンアルキニル化合物及びその塩 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004285923A1 (en) | 2003-10-27 | 2005-05-12 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| EP1968979A2 (en) * | 2005-12-08 | 2008-09-17 | Abbott Laboratories | 9-membered heterobicyclic compounds as inhibitors of protein kinases |
| CN101460161A (zh) | 2006-03-29 | 2009-06-17 | 弗尔德里克斯制药股份有限公司 | α-突触核蛋白毒性的抑制 |
| WO2008054827A2 (en) * | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| CN103319488A (zh) | 2007-03-28 | 2013-09-25 | 环状药物公司 | 布鲁顿氏酪氨酸激酶抑制剂 |
| JP2009235057A (ja) * | 2007-10-31 | 2009-10-15 | Santen Pharmaceut Co Ltd | 血管新生阻害活性を有する新規インドール誘導体 |
| CA3031835C (en) | 2008-06-27 | 2021-09-07 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| CN103857396A (zh) | 2011-07-13 | 2014-06-11 | 药品循环公司 | 布鲁顿酪氨酸激酶抑制剂 |
| WO2013010889A1 (en) * | 2011-07-15 | 2013-01-24 | Sanofi-Aventis Deutschland Gmbh | A drug delivery device |
| CN104250250A (zh) * | 2013-06-25 | 2014-12-31 | 苏州科捷生物医药有限公司 | 4-芳香胺基嘧啶类化合物及其抗肿瘤用途 |
-
2014
- 2014-08-11 US US14/784,239 patent/US9580432B2/en active Active
- 2014-08-11 MY MYPI2015704772A patent/MY171831A/en unknown
- 2014-08-11 KR KR1020167003396A patent/KR101828187B1/ko active Active
- 2014-08-11 AU AU2014307437A patent/AU2014307437B2/en active Active
- 2014-08-11 EP EP14836782.4A patent/EP2947086B1/en active Active
- 2014-08-11 PL PL14836782T patent/PL2947086T3/pl unknown
- 2014-08-11 TR TR2018/02875T patent/TR201802875T4/tr unknown
- 2014-08-11 RU RU2015156524A patent/RU2666349C2/ru active
- 2014-08-11 BR BR112016002069-3A patent/BR112016002069B1/pt active IP Right Grant
- 2014-08-11 HU HUE14836782A patent/HUE036834T2/hu unknown
- 2014-08-11 DK DK14836782.4T patent/DK2947086T3/en active
- 2014-08-11 ES ES14836782.4T patent/ES2661733T3/es active Active
- 2014-08-11 SG SG11201600048VA patent/SG11201600048VA/en unknown
- 2014-08-11 CN CN201480043405.1A patent/CN105452257B/zh active Active
- 2014-08-11 JP JP2015531804A patent/JP6035423B2/ja active Active
- 2014-08-11 PT PT148367824T patent/PT2947086T/pt unknown
- 2014-08-11 NO NO14836782A patent/NO2947086T3/no unknown
- 2014-08-11 TW TW103127536A patent/TWI585089B/zh active
- 2014-08-11 CA CA2921208A patent/CA2921208C/en active Active
- 2014-08-11 MX MX2016001845A patent/MX360498B/es active IP Right Grant
- 2014-08-11 WO PCT/JP2014/071158 patent/WO2015022926A1/ja not_active Ceased
-
2015
- 2015-12-07 PH PH12015502737A patent/PH12015502737B1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013108809A1 (ja) * | 2012-01-19 | 2013-07-25 | 大鵬薬品工業株式会社 | ３，５－二置換ベンゼンアルキニル化合物及びその塩 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014307437B2 (en) | Novel fused pyrimidine compound or salt thereof | |
| JP6084292B2 (ja) | Ｆｇｆｒ阻害剤耐性癌の治療薬 | |
| TWI574691B (zh) | Anti - tumor agents for intermittent administration of FGFR inhibitors | |
| TWI508964B (zh) | 3,5-di-substituted phenynyl compounds and salts thereof | |
| CN110914277B (zh) | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 | |
| JP2020504139A (ja) | キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途 | |
| CN106061980A (zh) | 作为mknk1和mknk2抑制剂的噻吩并嘧啶 | |
| AU2016213030B2 (en) | Preventive and/or therapeutic agent of immune disease | |
| WO2023059582A1 (en) | Heterobifunctional compounds and their use in treating disease | |
| HK1217703B (en) | Novel fused pyrimidine compound or salt thereof | |
| HK1198164B (en) | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |